Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome
Authors:
- The European Paediatric Study Group for HUSTHThe European Paediatric Study Group for HUS
- Diana KarpmanDKDiana Karpman
- C. Mark TaylorCTC. Mark Taylor
- Nicole Van de KarNKNicole Van de Kar
- 1 April 2009
- journal article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 24 (4) , 687-696
Abstract
This guideline for the investigation and initial treatment of atypical hemolytic uremic syndrome (HUS) is intended to offer an approach based on opinion, as evidence is lacking. It builds on the current ability to identify the etiology of specific diagnostic sub-groups of HUS. HUS in children is mostly due to infection, enterohemorrhagic Escherichia coli (EHEC), Shigella dysenteriae type 1 in some geographic regions, and invasive Streptococcus pneumoniae. These sub-groups are relatively straightforward to diagnose. Their management, which is outside the remit of this guideline, is related to control of infection where that is necessary and supportive measures for the anemia and acute renal failure. A thorough investigation of the remainder of childhood HUS cases, commonly referred to as “atypical” HUS, will reveal a risk factor for the syndrome in approximately 60% of cases. Disorders of complement regulation are, numerically, the most important. The outcome for children with atypical HUS is poor, and, because of the rarity of these disorders, clinical experience is scanty. Some cases of complement dysfunction appear to respond to plasma therapy. The therapeutic part of this guideline is the consensus of the contributing authors and is based on limited information from uncontrolled studies. The guideline proposes urgent and empirical plasmapheresis replacement with whole plasma fraction for the first month after diagnosis. This should only be undertaken in specialized pediatric nephrology centers where appropriate medical and nursing skills are available. The guideline includes defined terminology and audit points so that the early clinical effectiveness of the strategy can be evaluated.Keywords
This publication has 35 references indexed in Scilit:
- Shiga Toxin-Mediated Hemolytic Uremic Syndrome: Time to Change the Diagnostic Paradigm?PLOS ONE, 2007
- Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonatePediatric Nephrology, 2007
- Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndromeProceedings of the National Academy of Sciences, 2007
- Secondary failure of plasma therapy in factor H deficiencyPediatric Nephrology, 2006
- Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcomeBlood, 2006
- Blood pressure centiles for Great BritainArchives of Disease in Childhood, 2006
- An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutationsHuman Mutation, 2005
- Challenges in the management of infantile factor H associated hemolytic uremic syndromePediatric Nephrology, 2004
- Successful (?) therapy of hemolytic-uremic syndrome with factor H abnormalityPediatric Nephrology, 2003
- Successful treatment of factor H‐related haemolytic uraemic syndromeNephrology Dialysis Transplantation, 2002